GEN: Unlocking the Potential of Transcription Factors
How siRNA, omics, and AI could enable 100 new FDA approvals by 2045
co-founders Janine Sengstack and Rob Cahill share a foundational perspective on why transcription factors, once dismissed as “undruggable” and “too risky,” are now within reach.
Their article traces how advances in siRNA, omics, and AI/ML are converging to unlock transcription factors as one of the most powerful and overlooked target classes in medicine.
Resetting transcription factors could lead to a wave of FDA approvals, give new hope for treating our biggest diseases, and open the door to extending healthspan and lifespan.
Read the full article in Genetic Engineering & Biotechnology News: https://www.genengnews.com/topics/drug-discovery/unlocking-the-potential-of-transcription-factors/
Their article traces how advances in siRNA, omics, and AI/ML are converging to unlock transcription factors as one of the most powerful and overlooked target classes in medicine.
Resetting transcription factors could lead to a wave of FDA approvals, give new hope for treating our biggest diseases, and open the door to extending healthspan and lifespan.
Read the full article in Genetic Engineering & Biotechnology News: https://www.genengnews.com/topics/drug-discovery/unlocking-the-potential-of-transcription-factors/